CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A financial benchmark comprises defined scope, transparent methodology, and objective performance metrics to enable consistent comparison and evaluation.
16,759 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
As SpaceX moves toward an IPO, investors wonder which ETFs will own the company next. This guide breaks down how inde...
A federally funded health study tied to the Biden administration finds no safe level of alcohol and warns risks rise ...
The Amplify Seymour Cannabis ETF (CNBS) is up 105% over the past year, driven by investor bets on federal cannabis re...
Anthropic unveils Claude Mythos in a full cybersecurity-focused release, paired with a safer Fable 5 for general user...
Visa’s CFO signaled that stablecoins and agentic commerce are not material to near-term growth, as the payments giant...
A hotter-than-expected inflation reading paired with robust payroll gains left the newly named Fed chair navigating a...
A bipartisan House bill seeks to cut red tape in Buy America housing funding, aiming to speed projects that rely on H...
Intel reveals a slate of high-impact partnerships and capacity expansions that could redefine its role in AI and clou...
The 2026 COLA boosted Social Security checks, yet a fixed Medicare premium cut into those gains, changing how retiree...
Investors brace for the first rate hike since 2023 as the Fed under new chair Kevin Warsh faces sticky inflation and ...
When Anthropic faced a backlash over secret censorship in Claude Fable 5, the company apologized and promised safegua...